Methotrexate vs other DMARDs
Change in radiographic progression ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
124 questions · 139 findings · 15 reviews
No studies found 31 · 22.3%GRADE not reported 14 · 10.1%Very low 27 · 19.4%Low 39 · 28.1%Moderate 23 · 16.5%High 5 · 3.6%
Methotrexate vs other DMARDs
Serious adverse events (leflunomide) assessed by number of events · psoriatic arthritis
1 finding from 1 review
- no estimate extracted2 studies · 61 participantsVery low
Methotrexate vs other DMARDs
Withdrawals due to adverse events · psoriatic arthritis
2 findings from 1 review
- no estimate extracted2 studies · 61 participantsVery low
- RR 1.26 [0.33, 4.82]1 study · 35 participantsVery low
Methotrexate vs other DMARDs
Serious adverse events (ciclosporin A) assessed by number of events · psoriatic arthritis
1 finding from 1 review
- no estimate extracted1 study · 35 participantsVery low
Methotrexate vs placebo
Function · psoriatic arthritis
1 finding from 1 review
- no estimate extracted1 study · 221 participantsLow
Methotrexate vs placebo
Health‐related quality of life ‐ not reported · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
Disease activity · psoriatic arthritis
1 finding from 1 review
- no estimate extracted1 study · 221 participantsLow
Methotrexate vs placebo
Change in radiographic progression ‐ not measured · psoriatic arthritis
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Methotrexate vs placebo
SAEs · psoriatic arthritis
Methotrexate showed no clear difference in serious adverse events (SAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
- RR 0.26 [0.03, 2.26]3 studies · 293 participantsLow
Methotrexate vs placebo
Withdrawals due to adverse events · psoriatic arthritis
Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
- RR 1.32 [0.51, 3.42]3 studies · 293 participantsLow
Methotrexate vs other DMARDs
Disease response (leflunomide) · psoriatic arthritis
It is very uncertain whether methotrexate changes disease response (leflunomide) compared with other DMARDs (very low certainty).
1 finding from 1 review
- RR 1.05 [0.77, 1.45]1 study · 30 participantsVery low
Methotrexate vs other DMARDs
Function (leflunomide) · psoriatic arthritis
1 finding from 1 review
- no estimate extracted1 study · 31 participantsVery low
Methotrexate vs placebo
Maintenance of remission · Patients with quiescent ulcerative colitis
Methotrexate showed no clear difference in maintenance of remission compared with placebo (low certainty).
1 finding from 1 review
- Methotrexate for maintenance of remission in ulcerative colitis 2015 · Cochrane Headline outcomes onlyRR 0.64 [0.28, 1.45]1 study · 32 participantsLow
Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Maintenance of remission · Patients with quiescent ulcerative colitis
It is very uncertain whether methotrexate changes maintenance of remission compared with 5‐ASA (very low certainty).
1 finding from 1 review
- Methotrexate for maintenance of remission in ulcerative colitis 2015 · Cochrane Headline outcomes onlyRR 1.12 [0.06, 20.71]1 study · 9 participantsVery low
Methotrexate vs 6‐MP
Maintenance of remission · Maintenance of remission in ulcerative colitis
It is very uncertain whether methotrexate changes maintenance of Remission compared with 6‐MP (very low certainty).
1 finding from 1 review
- Methotrexate for maintenance of remission in ulcerative colitis 2015 · Cochrane Headline outcomes onlyRR 0.22 [0.03, 1.45]1 study · 18 participantsVery low
Methotrexate vs placebo
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
Methotrexate showed no clear difference in failure to enter remission or possible remission at 16 weeks (Arora… compared with placebo (low certainty).
3 findings from 1 review
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 3 [0.68, 13.31]1 study · 33 participantsLow
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 1.05 [0.79, 1.39]1 study · 52 participantsLow
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 0.75 [0.61, 0.93]1 study · 141 participantsModerate
Methotrexate vs 6‐MP or azathioprine
Adverse events (Ardizzone 2003) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes adverse events (Ardizzone 2003) compared with 6‐MP or azathioprine (very low certainty).
1 finding from 1 review
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 2.43 [1.21, 4.89]1 study · 54 participantsVery low
Methotrexate vs 6‐MP or azathioprine
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Oren 1997) compared with 6‐MP or azathioprine (very low certainty).
3 findings from 1 review
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 1.23 [0.08, 18.74]1 study · 58 participantsVery low
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 2.13 [0.22, 21.17]1 study · 31 participantsVery low
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 1 [0.22, 4.52]1 study · 54 participantsVery low
Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Failure to enter remission or possible remission at 16 weeks (Arora 1999) · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty).
1 finding from 1 review
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 0.23 [0.08, 0.67]1 study · 22 participantsVery low
Methotrexate vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)
Withdrawals due to adverse events · adult patients with refractory Crohn's disease
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Maté‐Jiménez 2000) compared with 5‐ASA (very low certainty).
1 finding from 1 review
- Methotrexate for induction of remission in refractory Crohn's disease 2014 · Cochrane Headline outcomes onlyRR 2.5 [0.14, 46.14]1 study · 22 participantsVery low